The hematopathological basis for studying effects of the demethylating agent 5-aza-2′-deoxycytidine (decitabine) in myelodysplasia View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2005-11-25

AUTHORS

Hans Eckart Schaefer, Michael Lübbert

ABSTRACT

The myelodysplastic syndromes have, since their first recognition decades ago, been considered notoriously difficult with regard to their proper classification, determination of prognosis, and optimal treatment. With the advent of the French–American–British (FAB) classification, now aided but not superseded by the World Health Organization classification, distinct biological entities have been delineated, which in turn are very useful for stratification to different, established and experimental treatment modalities. However, precise subclassification of different types of myelodysplastic syndrome (MDS) is only possible with hematopathological studies based on the analysis of peripheral blood, bone marrow smear, and bone marrow biopsy, backed by appropriate clinical information. Bone marrow cytogenetics are also essential for any risk stratification since they still provide the second most powerful prognostic parameter after bone marrow blast enumeration. This paper will review the most important aspects of hematopathological diagnostics in MDS, risk scoring, and their application to the inclusion and stratification of patients into the European Organization for Research and Treatment of Cancer (EORTC)/German MDS Study Group Phase III multicenter trial of low-dose decitabine in patients more than 60 years old with high-risk MDS. Emphasis is placed on itemizing the broad spectrum of cytologic and histologic stigmata defining the myelodysplastic categories that are to be considered in this study. More... »

PAGES

67-79

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00277-005-0034-8

DOI

http://dx.doi.org/10.1007/s00277-005-0034-8

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1041677456

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/16308721


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Cardiorespiratory Medicine and Haematology", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antimetabolites, Antineoplastic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Azacitidine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bone Marrow Examination", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cell Differentiation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "DNA Methylation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "DNA Modification Methylases", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Decitabine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Myelodysplastic Syndromes", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Institute of Pathology, University of Freiburg, POB 214, 79002, Freiburg, Germany", 
          "id": "http://www.grid.ac/institutes/grid.5963.9", 
          "name": [
            "Institute of Pathology, University of Freiburg, POB 214, 79002, Freiburg, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Schaefer", 
        "givenName": "Hans Eckart", 
        "id": "sg:person.01116304300.49", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01116304300.49"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medicine, Division of Haematology/Oncology, University of Freiburg Medical Center, Hugstetter Str. 55, 79106, Freiburg, Germany", 
          "id": "http://www.grid.ac/institutes/grid.7708.8", 
          "name": [
            "Department of Medicine, Division of Haematology/Oncology, University of Freiburg Medical Center, Hugstetter Str. 55, 79106, Freiburg, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "L\u00fcbbert", 
        "givenName": "Michael", 
        "id": "sg:person.01153663723.53", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01153663723.53"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/978-3-642-18514-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029983381", 
          "https://doi.org/10.1007/978-3-642-18514-4"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.leu.2400526", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004603814", 
          "https://doi.org/10.1038/sj.leu.2400526"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.thj.6200335", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1111238852", 
          "https://doi.org/10.1038/sj.thj.6200335"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/978-3-642-66094-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022961860", 
          "https://doi.org/10.1007/978-3-642-66094-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/251437a0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013471585", 
          "https://doi.org/10.1038/251437a0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00277-005-0012-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006807585", 
          "https://doi.org/10.1007/s00277-005-0012-1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.leu.2403189", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017741193", 
          "https://doi.org/10.1038/sj.leu.2403189"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf01634044", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023498409", 
          "https://doi.org/10.1007/bf01634044"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/978-3-642-92049-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009326277", 
          "https://doi.org/10.1007/978-3-642-92049-3"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf01488819", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031053562", 
          "https://doi.org/10.1007/bf01488819"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2005-11-25", 
    "datePublishedReg": "2005-11-25", 
    "description": "The myelodysplastic syndromes have, since their first recognition decades ago, been considered notoriously difficult with regard to their proper classification, determination of prognosis, and optimal treatment. With the advent of the French\u2013American\u2013British (FAB) classification, now aided but not superseded by the World Health Organization classification, distinct biological entities have been delineated, which in turn are very useful for stratification to different, established and experimental treatment modalities. However, precise subclassification of different types of myelodysplastic syndrome (MDS) is only possible with hematopathological studies based on the analysis of peripheral blood, bone marrow smear, and bone marrow biopsy, backed by appropriate clinical information. Bone marrow cytogenetics are also essential for any risk stratification since they still provide the second most powerful prognostic parameter after bone marrow blast enumeration. This paper will review the most important aspects of hematopathological diagnostics in MDS, risk scoring, and their application to the inclusion and stratification of patients into the European Organization for Research and Treatment of Cancer (EORTC)/German MDS Study Group Phase III multicenter trial of low-dose decitabine in patients more than 60\u00a0years old with high-risk MDS. Emphasis is placed on itemizing the broad spectrum of cytologic and histologic stigmata defining the myelodysplastic categories that are to be considered in this study.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s00277-005-0034-8", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1358129", 
        "issn": [
          "0939-5555", 
          "1432-0584"
        ], 
        "name": "Annals of Hematology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "Suppl 1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "84"
      }
    ], 
    "keywords": [
      "myelodysplastic syndrome", 
      "phase III multicenter trial", 
      "high-risk myelodysplastic syndrome", 
      "World Health Organization classification", 
      "low-dose decitabine", 
      "experimental treatment modality", 
      "bone marrow biopsy", 
      "stratification of patients", 
      "bone marrow cytogenetics", 
      "powerful prognostic parameter", 
      "determination of prognosis", 
      "bone marrow smears", 
      "appropriate clinical information", 
      "histologic stigmata", 
      "multicenter trial", 
      "risk stratification", 
      "marrow biopsy", 
      "treatment of cancer", 
      "British (FAB) classification", 
      "peripheral blood", 
      "prognostic parameters", 
      "optimal treatment", 
      "Organization classification", 
      "treatment modalities", 
      "marrow cytogenetics", 
      "distinct biological entities", 
      "demethylating agent 5", 
      "marrow smears", 
      "clinical information", 
      "precise subclassification", 
      "European Organization", 
      "risk scoring", 
      "agent 5", 
      "patients", 
      "syndrome", 
      "treatment", 
      "stratification", 
      "broad spectrum", 
      "myelodysplasia", 
      "prognosis", 
      "biopsy", 
      "proper classification", 
      "cancer", 
      "decitabine", 
      "smears", 
      "blood", 
      "subclassification", 
      "trials", 
      "modalities", 
      "study", 
      "cytogenetics", 
      "stigma", 
      "scoring", 
      "years", 
      "classification", 
      "entities", 
      "effect", 
      "important aspect", 
      "different types", 
      "regard", 
      "diagnostics", 
      "categories", 
      "inclusion", 
      "advent", 
      "types", 
      "decades", 
      "analysis", 
      "aspects", 
      "emphasis", 
      "information", 
      "enumeration", 
      "basis", 
      "research", 
      "biological entities", 
      "turn", 
      "organization", 
      "determination", 
      "parameters", 
      "spectra", 
      "applications", 
      "paper"
    ], 
    "name": "The hematopathological basis for studying effects of the demethylating agent 5-aza-2\u2032-deoxycytidine (decitabine) in myelodysplasia", 
    "pagination": "67-79", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1041677456"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00277-005-0034-8"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "16308721"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00277-005-0034-8", 
      "https://app.dimensions.ai/details/publication/pub.1041677456"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-12-01T06:25", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221201/entities/gbq_results/article/article_404.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s00277-005-0034-8"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00277-005-0034-8'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00277-005-0034-8'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00277-005-0034-8'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00277-005-0034-8'


 

This table displays all metadata directly associated to this object as RDF triples.

228 TRIPLES      21 PREDICATES      125 URIs      107 LITERALS      16 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00277-005-0034-8 schema:about N208c5878543a4e4cad7449540411aaba
2 N5a62faf17ee34601b76987340af57b61
3 N6df56480b3d1419b8653955e51dc1b80
4 N8db0d8fb36bf48a0847a40fd2299b374
5 Nae4ee450781b422ca09584372ed9cd76
6 Nb7cc503b99c446708685e80f9691654c
7 Nc5cf21fe15774f829c1c86d023b7e8ee
8 Nd00579d626be40a9a099c16962eacce7
9 Nffc474d2ec504f7597f57e34cb223ade
10 anzsrc-for:11
11 anzsrc-for:1102
12 schema:author N449736ba66124548a1d6fa76aee3717f
13 schema:citation sg:pub.10.1007/978-3-642-18514-4
14 sg:pub.10.1007/978-3-642-66094-8
15 sg:pub.10.1007/978-3-642-92049-3
16 sg:pub.10.1007/bf01488819
17 sg:pub.10.1007/bf01634044
18 sg:pub.10.1007/s00277-005-0012-1
19 sg:pub.10.1038/251437a0
20 sg:pub.10.1038/sj.leu.2400526
21 sg:pub.10.1038/sj.leu.2403189
22 sg:pub.10.1038/sj.thj.6200335
23 schema:datePublished 2005-11-25
24 schema:datePublishedReg 2005-11-25
25 schema:description The myelodysplastic syndromes have, since their first recognition decades ago, been considered notoriously difficult with regard to their proper classification, determination of prognosis, and optimal treatment. With the advent of the French–American–British (FAB) classification, now aided but not superseded by the World Health Organization classification, distinct biological entities have been delineated, which in turn are very useful for stratification to different, established and experimental treatment modalities. However, precise subclassification of different types of myelodysplastic syndrome (MDS) is only possible with hematopathological studies based on the analysis of peripheral blood, bone marrow smear, and bone marrow biopsy, backed by appropriate clinical information. Bone marrow cytogenetics are also essential for any risk stratification since they still provide the second most powerful prognostic parameter after bone marrow blast enumeration. This paper will review the most important aspects of hematopathological diagnostics in MDS, risk scoring, and their application to the inclusion and stratification of patients into the European Organization for Research and Treatment of Cancer (EORTC)/German MDS Study Group Phase III multicenter trial of low-dose decitabine in patients more than 60 years old with high-risk MDS. Emphasis is placed on itemizing the broad spectrum of cytologic and histologic stigmata defining the myelodysplastic categories that are to be considered in this study.
26 schema:genre article
27 schema:isAccessibleForFree false
28 schema:isPartOf N3b6d193cf31043f5a25f48346fbe66ea
29 Ncb0db8f2d2e3448dabfddf900f350d77
30 sg:journal.1358129
31 schema:keywords British (FAB) classification
32 European Organization
33 Organization classification
34 World Health Organization classification
35 advent
36 agent 5
37 analysis
38 applications
39 appropriate clinical information
40 aspects
41 basis
42 biological entities
43 biopsy
44 blood
45 bone marrow biopsy
46 bone marrow cytogenetics
47 bone marrow smears
48 broad spectrum
49 cancer
50 categories
51 classification
52 clinical information
53 cytogenetics
54 decades
55 decitabine
56 demethylating agent 5
57 determination
58 determination of prognosis
59 diagnostics
60 different types
61 distinct biological entities
62 effect
63 emphasis
64 entities
65 enumeration
66 experimental treatment modality
67 high-risk myelodysplastic syndrome
68 histologic stigmata
69 important aspect
70 inclusion
71 information
72 low-dose decitabine
73 marrow biopsy
74 marrow cytogenetics
75 marrow smears
76 modalities
77 multicenter trial
78 myelodysplasia
79 myelodysplastic syndrome
80 optimal treatment
81 organization
82 paper
83 parameters
84 patients
85 peripheral blood
86 phase III multicenter trial
87 powerful prognostic parameter
88 precise subclassification
89 prognosis
90 prognostic parameters
91 proper classification
92 regard
93 research
94 risk scoring
95 risk stratification
96 scoring
97 smears
98 spectra
99 stigma
100 stratification
101 stratification of patients
102 study
103 subclassification
104 syndrome
105 treatment
106 treatment modalities
107 treatment of cancer
108 trials
109 turn
110 types
111 years
112 schema:name The hematopathological basis for studying effects of the demethylating agent 5-aza-2′-deoxycytidine (decitabine) in myelodysplasia
113 schema:pagination 67-79
114 schema:productId N2648fa73048f4c77a866c85780f5204f
115 N4e21051bb6c94077a6e6aecfc5ee1165
116 Nc4cce28ccd7c43729eff744b68d82563
117 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041677456
118 https://doi.org/10.1007/s00277-005-0034-8
119 schema:sdDatePublished 2022-12-01T06:25
120 schema:sdLicense https://scigraph.springernature.com/explorer/license/
121 schema:sdPublisher N344a906b808e40c280a46f58c3491900
122 schema:url https://doi.org/10.1007/s00277-005-0034-8
123 sgo:license sg:explorer/license/
124 sgo:sdDataset articles
125 rdf:type schema:ScholarlyArticle
126 N208c5878543a4e4cad7449540411aaba schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
127 schema:name DNA Methylation
128 rdf:type schema:DefinedTerm
129 N2648fa73048f4c77a866c85780f5204f schema:name pubmed_id
130 schema:value 16308721
131 rdf:type schema:PropertyValue
132 N344a906b808e40c280a46f58c3491900 schema:name Springer Nature - SN SciGraph project
133 rdf:type schema:Organization
134 N3b6d193cf31043f5a25f48346fbe66ea schema:issueNumber Suppl 1
135 rdf:type schema:PublicationIssue
136 N449736ba66124548a1d6fa76aee3717f rdf:first sg:person.01116304300.49
137 rdf:rest N571434aad0b74cec82c17ccdc8ad08d9
138 N4e21051bb6c94077a6e6aecfc5ee1165 schema:name doi
139 schema:value 10.1007/s00277-005-0034-8
140 rdf:type schema:PropertyValue
141 N571434aad0b74cec82c17ccdc8ad08d9 rdf:first sg:person.01153663723.53
142 rdf:rest rdf:nil
143 N5a62faf17ee34601b76987340af57b61 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Azacitidine
145 rdf:type schema:DefinedTerm
146 N6df56480b3d1419b8653955e51dc1b80 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name DNA Modification Methylases
148 rdf:type schema:DefinedTerm
149 N8db0d8fb36bf48a0847a40fd2299b374 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
150 schema:name Myelodysplastic Syndromes
151 rdf:type schema:DefinedTerm
152 Nae4ee450781b422ca09584372ed9cd76 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
153 schema:name Cell Differentiation
154 rdf:type schema:DefinedTerm
155 Nb7cc503b99c446708685e80f9691654c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
156 schema:name Antimetabolites, Antineoplastic
157 rdf:type schema:DefinedTerm
158 Nc4cce28ccd7c43729eff744b68d82563 schema:name dimensions_id
159 schema:value pub.1041677456
160 rdf:type schema:PropertyValue
161 Nc5cf21fe15774f829c1c86d023b7e8ee schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
162 schema:name Humans
163 rdf:type schema:DefinedTerm
164 Ncb0db8f2d2e3448dabfddf900f350d77 schema:volumeNumber 84
165 rdf:type schema:PublicationVolume
166 Nd00579d626be40a9a099c16962eacce7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
167 schema:name Bone Marrow Examination
168 rdf:type schema:DefinedTerm
169 Nffc474d2ec504f7597f57e34cb223ade schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
170 schema:name Decitabine
171 rdf:type schema:DefinedTerm
172 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
173 schema:name Medical and Health Sciences
174 rdf:type schema:DefinedTerm
175 anzsrc-for:1102 schema:inDefinedTermSet anzsrc-for:
176 schema:name Cardiorespiratory Medicine and Haematology
177 rdf:type schema:DefinedTerm
178 sg:journal.1358129 schema:issn 0939-5555
179 1432-0584
180 schema:name Annals of Hematology
181 schema:publisher Springer Nature
182 rdf:type schema:Periodical
183 sg:person.01116304300.49 schema:affiliation grid-institutes:grid.5963.9
184 schema:familyName Schaefer
185 schema:givenName Hans Eckart
186 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01116304300.49
187 rdf:type schema:Person
188 sg:person.01153663723.53 schema:affiliation grid-institutes:grid.7708.8
189 schema:familyName Lübbert
190 schema:givenName Michael
191 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01153663723.53
192 rdf:type schema:Person
193 sg:pub.10.1007/978-3-642-18514-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029983381
194 https://doi.org/10.1007/978-3-642-18514-4
195 rdf:type schema:CreativeWork
196 sg:pub.10.1007/978-3-642-66094-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022961860
197 https://doi.org/10.1007/978-3-642-66094-8
198 rdf:type schema:CreativeWork
199 sg:pub.10.1007/978-3-642-92049-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009326277
200 https://doi.org/10.1007/978-3-642-92049-3
201 rdf:type schema:CreativeWork
202 sg:pub.10.1007/bf01488819 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031053562
203 https://doi.org/10.1007/bf01488819
204 rdf:type schema:CreativeWork
205 sg:pub.10.1007/bf01634044 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023498409
206 https://doi.org/10.1007/bf01634044
207 rdf:type schema:CreativeWork
208 sg:pub.10.1007/s00277-005-0012-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006807585
209 https://doi.org/10.1007/s00277-005-0012-1
210 rdf:type schema:CreativeWork
211 sg:pub.10.1038/251437a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013471585
212 https://doi.org/10.1038/251437a0
213 rdf:type schema:CreativeWork
214 sg:pub.10.1038/sj.leu.2400526 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004603814
215 https://doi.org/10.1038/sj.leu.2400526
216 rdf:type schema:CreativeWork
217 sg:pub.10.1038/sj.leu.2403189 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017741193
218 https://doi.org/10.1038/sj.leu.2403189
219 rdf:type schema:CreativeWork
220 sg:pub.10.1038/sj.thj.6200335 schema:sameAs https://app.dimensions.ai/details/publication/pub.1111238852
221 https://doi.org/10.1038/sj.thj.6200335
222 rdf:type schema:CreativeWork
223 grid-institutes:grid.5963.9 schema:alternateName Institute of Pathology, University of Freiburg, POB 214, 79002, Freiburg, Germany
224 schema:name Institute of Pathology, University of Freiburg, POB 214, 79002, Freiburg, Germany
225 rdf:type schema:Organization
226 grid-institutes:grid.7708.8 schema:alternateName Department of Medicine, Division of Haematology/Oncology, University of Freiburg Medical Center, Hugstetter Str. 55, 79106, Freiburg, Germany
227 schema:name Department of Medicine, Division of Haematology/Oncology, University of Freiburg Medical Center, Hugstetter Str. 55, 79106, Freiburg, Germany
228 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...